5432752026-05-245432752026-05-242026-05-245432752026-05-24in-capmkt:FinancialYear1Member5432752026-05-24in-capmkt:FinancialYear2Member5432752026-05-24in-capmkt:FinancialYear3Member5432752026-05-242026-05-24in-capmkt:FinancialYear1Member5432752026-05-242026-05-24in-capmkt:FinancialYear2Member5432752026-05-242026-05-24in-capmkt:FinancialYear3Memberiso4217:INRxbrli:pure543275ANUPAM RASAYAN INDIA LIMITEDANURASNOTLISTEDINE930P01018NewAcquisition (including agreement to acquire)true2026-05-2316:55:002026-05-24ANUPAM RASAYAN INDIA LIMITEDListed Entity (self)Bliss GVS Pharma Limited1000640000096870000012317600000falsefalsefalsefalsePharmaceuticalsThe proposed acquisition of the Target Company would strategically strengthen the Company's presence across the pharmaceutical value chain, spanning KSMs to finished dosage formulations. The Target Company’s established capabilities in niche dosage forms, differentiated brands, strong international footprint, and expertise across multiple therapeutic segments, combined with the Company’s advanced chemistry capabilities, would create a more integrated and diversified pharmaceutical manufacturing platform. The acquisition is expected to enhance forward integration and unlock significant synergies through innovation and operational efficiencies, thereby supporting sustainable long-term growth and value creation.NAfalseThe Share Acquisition is subject to completion of certain customary conditions and is expected to be completed within 6 months. The Open Offer will be completed in accordance with the Takeover Regulations.Cash13695100000The consideration agreed under the SPA is INR 1369.51 crores which means INR 299 per equity share for the acquisition of 43.30 percent by the Company, the acquisition of the Option Shares, if so undertaken by the Company, will take place at INR 299 per equity share and the acquisition of the Retained Shares will take place at the prevailing market price as on the date of acquisition of the Retained Shares except in the event the prevailing market price as on the date of acquisition of the Retained Shares is less than INR 299 per Equity Share, in which case the Retained Shares will be acquired off-market at a price of INR 299 per Equity Share, pursuant to a call option available with the Company in terms of the SPA.136951000000The Target Company is a public listed company incorporated under the provisions of the Companies Act, 1956. The Target Company is engaged in the business of manufacturing of pharmaceutical products including suppositories, pessaries, tablets, capsules, and other specialty pharmaceutical products.1984-12-112025-2026100064000002024-202584622000002023-20247989800000The Target Company has a global footprint in over 60 plus countries with its most dominant market being Sub-Saharan Africa.Upon acquisition of equity shares of the Target Company as contemplated under the SPA, the Company will acquire control over the Target Company and be categorized as a promoter of the Target Company.